RESISTANT HYPERTENSION CLINICAL TRIAL INSIGHT, PIPELINE ASSESSMENT, EMERGING DRUGS | DELVEINSIGHT
DelveInsight has launched a report on “ Resistant Hypertension Pipeline Insight, 2020 ”
“Resistant Hypertension Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Resistant Hypertension market. A detailed picture of the Resistant Hypertension pipeline landscape is provided, which includes the disease overview and Resistant Hypertension treatment guidelines.
The assessment part of the report embraces in-depth Resistant Hypertension commercial assessment and clinical assessment of the Resistant Hypertension pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Resistant Hypertension collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Some of the key companies working on Resistant Hypertension are:
- Idorsia Pharmaceuticals
- Quantum Genomics
- Novartis
- Relypsa
And Many Others.
The launch of the emerging therapies is expected to significantly impact the Resistant Hypertension treatment scenario in the upcoming years:-
Drugs Covered:
- Aprocitentan
- Firibastat
- LHW090
- Veltassa
And Many Others.
Resistant Hypertension Analytical Perspective by DelveInsight
- In-depth Resistant Hypertension Commercial Assessment of products
This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.
- Resistant Hypertension Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Scope of the report
- The Resistant Hypertension report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Resistant Hypertension across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Resistant Hypertension therapeutic productswith key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Resistant Hypertension research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Resistant Hypertension.
Report highlights
- A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Resistant Hypertension.
- In the coming years, the Resistant Hypertension market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics that are working to assess challenges and seek opportunities that could influence Resistant Hypertension R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- A detailed portfolio of major pharma players who are involved in fueling the Resistant Hypertension treatment market. Several potential therapies for Resistant Hypertension are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Resistant Hypertension market size in the coming years.
- Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Resistant Hypertension) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Key Questions
- What are the current options for Resistant Hypertensiontreatment?
- How many companies are developing therapies for the treatment of Resistant Hypertension?
- What are the principal therapies developed by these companies in the industry?
- How many therapies are developed by each company for the treatment of Resistant Hypertension?
- How many Resistant Hypertension emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Resistant Hypertension?
- Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Resistant Hypertension market?
- Which are the dormant and discontinued products and the reasons for the same?
- What is the unmet need for current therapies for the treatment of Resistant Hypertension?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Resistant Hypertensiontherapies?
- What are the clinical studies going on for Resistant Hypertension and their status?
- What are the results of the clinical studies and their safety and efficacy?
- What are the key designations that have been granted for the emerging therapies for Resistant Hypertension?
- How many patents are granted and pending for the emerging therapies for the treatment of Resistant Hypertension?
Table of Contents
1. Report Introduction
2. Resistant Hypertension
2.1. Overview
2.2. History
2.3. Resistant Hypertension Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Resistant Hypertension Diagnosis
2.6.1. Diagnostic Guidelines
3. Resistant Hypertension Current Treatment Patterns
3.1. Resistant Hypertension Treatment Guidelines
4. Resistant Hypertension – DelveInsight’s Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Resistant Hypertension companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Resistant Hypertension Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Resistant Hypertension Late Stage Products (Phase-III)
7. Resistant Hypertension Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Resistant Hypertension Discontinued Products
13. Resistant Hypertension Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
Detailed information in the report?
14. Resistant Hypertension Key Companies
15. Resistant Hypertension Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Resistant Hypertension Unmet Needs
18. Resistant Hypertension Future Perspectives
19. Resistant Hypertension Analyst Review
20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
